

GLOBAL MARKETS AND TECHNOLOGIES FOR PANDEMIC CONTROL



PHM042B

Peggy Lehr
Project Analyst

ISBN: 1-56965-132-9

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports:
carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
METHODOLOGY/INFORMATION SOURCES	3
INTENDED AUDIENCE	3
ANALYST CREDENTIALS	3
RELATED BCC REPORTS	4
BCC ONLINE SERVICES	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE PROJECTED MARKET FOR PANDEMIC INFECTIOUS DISEASE PRODUCTS, BY DISEASE TYPE, THROUGH 2017 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE PROJECTED MARKET FOR PANDEMIC INFECTIOUS DISEASE PRODUCTS, BY REGION, 2012 AND 2017 (%)</i>	7
CHAPTER 3 OVERVIEW	10
PATHOGENIC MICROBES AND INFECTIOUS DISEASES RECOGNIZED BETWEEN 1973 AND 2009	10
<i>TABLE 1 DISEASE-CAUSING BACTERIA, PARASITES, AND VIRUSES IDENTIFIED BETWEEN 1973 AND 2009</i>	10
FACTORS IN THE EMERGENCE OF INFECTIOUS DISEASES	11
HUMAN DEMOGRAPHICS AND BEHAVIOR	12
TECHNOLOGY	12
THE ROLE OF NEEDLES	12
ECONOMIC DEVELOPMENT AND LAND USE	12
INTERNATIONAL TRAVEL	13
MICROBIAL ADAPTATION	13
ANTIBIOTIC DEVELOPMENT	13
<i>TABLE 2 HISTORY OF ANTIBIOTIC DISCOVERY AND APPROVAL, 1935-2003</i>	13
CLASSIFYING VIRAL OUTBREAKS, EPIDEMICS AND PANDEMICS	14
<i>TABLE 3 CDC'S SIX PHASES OF CLASSIFICATION OF VIRAL PANDEMICS</i>	14
CURRENT AND POTENTIAL EPIDEMICS WITH PANDEMIC POTENTIAL	14
<i>TABLE 4 MAJOR INFECTIOUS DISEASES WITH TYPE OF DISEASE, NUMBER OF CASES, AND POTENTIAL AS A PANDEMIC, 2011</i>	15
CURRENT AND POTENTIAL PANDEMICS	16
CURRENT TECHNOLOGIES FOR ADDRESSING POTENTIAL PANDEMIC THREATS	16
<i>TABLE 5 TECHNOLOGIES TO ADDRESS POTENTIAL PANDEMIC THREATS</i>	17
BIOLOGICAL WEAPONS FOR TERRORISM	17
<i>TABLE 6 DISEASES THAT COULD BE OR HAVE BEEN WEAPONIZED</i>	18
THE NEXT PANDEMIC	18
TYPES OF ZOOONOTIC VIRUSES	19
A BRIEF HISTORY OF GLOBAL PANDEMICS	19
BUBONIC PLAGUE (1300 TO PRESENT)	19
CHOLERA (1916 TO 1966)	20
THE SPANISH INFLUENZA PANDEMIC (1918)	20

TOPIC	PAGE NO.
ASIAN FLU PANDEMIC (1957 TO 1958)	20
HIV/AIDS PANDEMIC (1980 TO PRESENT)	21
INFLUENZA A-H1N1 (2009 TO PRESENT)	21
MALARIA (2700 BC TO PRESENT)	21
SEVERE ACUTE RESPIRATORY SYNDROME (SARS) (2002 TO 2003)	22
SMALLPOX (15TH CENTURY TO 1979)	22
TUBERCULOSIS (4000 BC TO PRESENT)	22
TREATMENTS FOR INFECTIOUS DISEASES	23
PREVENTION	23
VACCINATION	23
PHARMACEUTICAL TREATMENTS	23
OPPORTUNITIES TO FIGHT POTENTIAL PANDEMIC INFECTIOUS DISEASES	24
BIOINFORMATION AND REMOTE SENSING MARKET	24
MERGERS AND ACQUISITIONS	24
<i>TABLE 7 SELECTED MERGERS AND ACQUISITIONS, 2008-2012 (\$ MILLIONS)</i>	25
CHAPTER 4 VACCINES, DIAGNOSTIC TESTING, AND PHARMACEUTICAL MARKETS FOR INFECTIOUS DISEASES	27
VACCINES	27
<i>TABLE 8 MAJOR MANUFACTURERS OF VACCINES FOR CURRENT AND POTENTIAL PANDEMICS</i>	28
TYPES OF DIAGNOSTIC TESTING	28
FLUORESCENT IMMUNOASSAY (FIA)	29
Direct Fluorescent Antibody Testing	29
Indirect Fluorescent Antibody Testing	29
Chemiluminescent Microparticle Immunoassay (CIA)	29
Chemiluminescent Microparticle Immunoassay (CIA)	29
ENZYME IMMUNOASSAY	30
Basic EIA	30
Enzyme-linked Immunosorbent Assay (ELISA)	30
GENE PROBE ANALYSIS	31
Polymerase Chain Reaction Amplification	31
Nucleic Acid Amplification Test (NAT)	31
Transcription-Mediated Amplification (TMA)	32
Nucleic Acid Sequence-Based Amplification (NASBA)	32
MARKET ANALYSIS, BY DISEASE	32
HEPATITIS B AND C	32
Diagnostic Product Market	33
<i>TABLE 9 HEPATITIS B AND C DIAGNOSTIC PRODUCT MARKET BY TYPE OF TEST, 2011 (\$ MILLIONS/%)</i>	33
<i>TABLE 10 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND C, 2012</i>	33
Automated Infectious Disease Testing for Hepatitis	35
Treatment Market	35
<i>TABLE 11 HEPATITIS B AND C TREATMENT MANUFACTURER MARKET STANDING, BY REVENUE, 2011 (\$ MILLIONS)</i>	36
<i>FIGURE 1 TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET AND THEIR MARKET SHARE, 2011 (%)</i>	36

TOPIC	PAGE NO.
Vaccines and Medications for Hepatitis	37
<i>TABLE 12 VACCINES AND MEDICATIONS FOR THE TREATMENT OF HEPATITIS, 2012</i>	37
HIV/AIDS	38
Diagnostic Market	38
<i>TABLE 13 HIV DIAGNOSTIC PRODUCT MARKET SHARE, 2011 (\$ MILLIONS/%)</i>	38
<i>TABLE 14 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HIV/AIDS, 2012</i>	38
Treatments	39
<i>TABLE 15 HIV LIFE CYCLE</i>	40
Nucleoside Reverse Transcriptase Inhibitors (NRTI)	40
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI)	40
Protease Inhibitors (PI)	40
Entry Inhibitors	41
Integrase Inhibitors	41
Multi-class Combination	41
Generic Treatments	41
<i>TABLE 16 FDA-APPROVED GENERIC DRUGS FOR TREATMENT OF HIV, 2004 TO 2012</i>	41
Brand Name HIV Treatments	42
<i>TABLE 17 CURRENTLY APPROVED PHARMACEUTICAL PRODUCTS FOR TREATMENT OF HIV/AIDS, 2012</i>	43
BRANDED TREATMENT MARKET, BY MAJOR MANUFACTURER	44
<i>TABLE 18 HIV TREATMENT MARKET BY MANUFACTURER, 2011 (\$ MILLIONS)</i>	44
<i>FIGURE 2 MARKET SHARE FOR BRANDED HIV DRUGS BY MANUFACTURER, 2011 (%)</i>	44
INFLUENZA	45
Pandemic Influenza (H1N1)	46
Diagnostic Products	46
<i>TABLE 19 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF PANDEMIC INFLUENZA, 2012</i>	46
Pharmaceutical Products	46
<i>TABLE 20 CURRENT PHARMACEUTICALS APPROPRIATE FOR TREATMENT OF PANDEMIC INFLUENZA</i>	47
MALARIA	47
Mosquito Netting	47
<i>TABLE 21 WHO RECOMMENDED MOSQUITO NETTING, 2012</i>	48
Diagnosis of Malaria	48
<i>TABLE 22 AVAILABLE MALARIA DIAGNOSTIC METHODS</i>	49
Diagnostic Tests of Malaria	49
<i>TABLE 23 CURRENT RAPID DIAGNOSTIC TESTS FOR DETECTION OF MALARIA</i>	49
Pharmaceutical Treatments for Malaria	50
<i>TABLE 24 PHARMACEUTICAL PRODUCTS USED TO TREAT MALARIA, 2012</i>	51
TUBERCULOSIS	51
Diagnostic Products	51
<i>TABLE 25 CURRENT DIAGNOSTIC TESTS FOR DETECTION OF TUBERCULOSIS, 2012</i>	52
Pharmaceutical Products	52

TOPIC	PAGE NO.
<i>TABLE 26 DRUGS USED TO TREAT TB</i>	52
CHAPTER 5 DISEASE OVERVIEW	55
<i>TABLE 27 CAUSATIVE ORGANISMS FOR PANDEMIC DISEASES</i>	55
ANTHRAX	55
OVERVIEW	55
RISK FACTORS	55
INCIDENCE	56
DIAGNOSTIC PROCEDURES	56
TREATMENTS	56
<i>TABLE 28 VACCINES AND MEDICATIONS FOR THE TREATMENT OF ANTHRAX, 2012</i>	56
CHOLERA	57
OVERVIEW	57
RISK FACTORS	57
INCIDENCE	57
DIAGNOSTIC PROCEDURES	57
<i>TABLE 29 CURRENT DIAGNOSTIC TESTS FOR CHOLERA</i>	57
TREATMENT	58
HEPATITIS B AND C	58
OVERVIEW	58
RISK FACTORS	59
INCIDENCE	59
Hepatitis in the U.S.	59
Hepatitis C in the U.S.	59
Hepatitis in Canada	59
Hepatitis B and C in EMRA	59
Hepatitis in Africa	60
Hepatitis in Russia, Eurasia	60
Hepatitis in Japan	61
Hepatitis in China	61
Hepatitis in India	61
Hepatitis in Australia	61
TREATMENTS	61
HIV/AIDS	61
OVERVIEW	61
<i>TABLE 30 CDC CLASSIFICATION OF HIV INFECTION</i>	62
RISK FACTORS	63
INCIDENCE/MORTALITY	63
HIV in the U.S.	63
HIV and Women in the U.S.	64
HIV in Canada	64
HIV in Latin and South America	64
HIV Treatment in Central/South America	64
HIV/AIDS in the EMRA	65
HIV in Africa	65
Access to Therapeutics in Africa	65
Russia, Eastern Europe, Central Asia	66

TOPIC	PAGE NO.
HIV Treatments in the Region	66
HIV in the Middle East	66
HIV in Sub-Saharan Africa	66
HIV/AIDS in Asia	67
HIV in Japan	67
HIV in India	67
HIV Testing/Treatment in India	67
HIV in China	68
HIV Testing and Treatment in China	68
Estimated Active Pharmaceutical Ingredients Needed	69
<i>TABLE 31 PROJECTED NEED FOR API TO MEET CORE ARV PRODUCT REQUIREMENTS, 2011 AND 2015</i>	69
INFLUENZA	69
OVERVIEW	69
Vaccines	69
New Production Techniques for Developing Influenza Vaccines	70
H1N1	70
H5N1	70
Mutations that Transform H5N1 into Pandemic Influenza	70
Pandemic Risk	71
Risk Factors	71
Incidence/Mortality	72
MALARIA	72
OVERVIEW	72
RISK FACTORS	72
Biological Characteristics	72
INCIDENCE/MORTALITY	73
TREATMENT MARKET	73
SEVERE ACUTE RESPIRATORY SYNDROME (SARS)	73
OUTBREAK LOCALES	73
INFECTION AND TRANSMISSION	74
TREATMENT	74
TUBERCULOSIS	74
OVERVIEW	74
RISK FACTORS	74
INCIDENCE/MORTALITY	75
HEMORRHAGIC FEVERS	75
ARENAVIRUSES	76
BUNYAVIRUSES	76
FILOVIRUSES	76
FLAVIVIRUSES	77
RISK	77
PANDEMIC POTENTIAL FOR HEMORRHAGIC VIRUSES	77
CHAPTER 6 VIRAL PANDEMIC THREATS AND TREATMENTS	80
WHAT IS A VIRUS?	80
PROJECTED GLOBAL MARKET FOR VACCINES, DIAGNOSTICS AND PHARMACEUTICALS	80

TOPIC	PAGE NO.
<i>TABLE 32 PROJECTED GLOBAL MARKET FOR VIRAL HIV AND HEPATITIS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	80
GLOBAL DIAGNOSTIC MARKET FOR HIV AND HEPATITIS	81
MARKET FOR VIRAL DISEASE DIAGNOSTIC PRODUCTS	81
<i>TABLE 33 PROJECTED GLOBAL MARKET FOR DIAGNOSTIC PRODUCTS USED TO DETECT HIV AND HEPATITIS PANDEMIC DISEASES, THROUGH 2017 (\$ MILLIONS)</i>	81
<i>FIGURE 3 PROJECTED GLOBAL MARKET FOR DIAGNOSTIC PRODUCTS USED TO DETECT HIV AND HEPATITIS PANDEMIC DISEASES, 2012 AND 2017 (%)</i>	81
VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS, BY DISEASE	82
<i>TABLE 34 PROJECTED GLOBAL MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	83
<i>FIGURE 4 GLOBAL MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS, 2012 AND 2017 (%)</i>	83
HEPATITIS	84
<i>TABLE 35 HEPATITIS CHARACTERISTICS BY TYPE</i>	84
<i>TABLE 36 PROJECTED GLOBAL MARKET FOR HEPATITIS DIAGNOSTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	85
<i>TABLE 37 PROJECTED GLOBAL MARKET FOR HEPATITIS VACCINE AND PHARMACEUTICALS, THROUGH 2017 (\$ MILLIONS)</i>	86
HEPATITIS A	86
<i>TABLE 38 PROJECTED REVENUE FROM HEPATITIS A TREATMENTS, THROUGH 2017 (\$ MILLIONS)</i>	86
HEPATITIS B	87
<i>TABLE 39 PROJECTED GLOBAL REVENUE FROM HEPATITIS PHARMACEUTICALS AND VACCINATIONS, THROUGH 2017 (\$ MILLIONS)</i>	87
HEPATITIS C	87
<i>TABLE 40 PROJECTED GLOBAL REVENUE FROM HEPATITIS C PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)</i>	87
<i>FIGURE 5 MARKET SHARES FOR HEPATITIS C TREATMENTS, 2010 (%)</i>	88
REGIONAL ANALYSIS	88
<i>TABLE 41 PROJECTED GLOBAL MARKET FOR VIRAL PANDEMIC DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	89
PROJECTED GLOBAL MARKET FOR VIRAL PANDEMIC DIAGNOSTIC PRODUCTS, BY REGION	89
<i>TABLE 42 PROJECTED GLOBAL MARKET FOR VIRAL PANDEMIC DIAGNOSTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	89
<i>FIGURE 6 GLOBAL PANDEMIC VIRAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, 2012 AND 2017 (%)</i>	89
<i>TABLE 43 PROJECTED GLOBAL MARKET FOR PANDEMIC PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	91
<i>FIGURE 7 GLOBAL PANDEMIC PHARMACEUTICAL MARKET, 2012 AND 2017 (%)</i>	91
AMERICAS	92
<i>TABLE 44 PROJECTED AMERICAS MARKET FOR VIRAL PANDEMIC DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	92
<i>TABLE 45 PROJECTED MARKET FOR VIRAL PANDEMIC DIAGNOSTIC PRODUCTS IN THE AMERICAS, THROUGH 2017 (\$ MILLIONS)</i>	93

TOPIC	PAGE NO.
<i>TABLE 46 PROJECTED MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS IN THE AMERICAS, THROUGH 2017 (\$ MILLIONS)</i>	93
EMRA	93
<i>TABLE 47 PROJECTED EMRA MARKET FOR VIRAL PANDEMIC DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	94
DIAGNOSTIC MARKET IN EMRA	94
<i>TABLE 48 PROJECTED EMRA MARKET FOR VIRAL PANDEMIC DIAGNOSTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	94
<i>TABLE 49 PROJECTED EMRA MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	95
ASIA	95
<i>TABLE 50 PROJECTED ASIAN MARKET FOR VIRAL PANDEMIC DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	95
DIAGNOSTIC PRODUCTS IN ASIA	95
<i>TABLE 51 PROJECTED MARKET FOR VIRAL PANDEMIC DIAGNOSTIC PRODUCTS IN ASIA, THROUGH 2017 (\$ MILLIONS)</i>	96
<i>FIGURE 8 MARKET FOR PANDEMIC DIAGNOSTIC PRODUCTS IN ASIA 2012 AND 2017 (%)</i>	96
<i>TABLE 52 PROJECTED MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS IN ASIA, THROUGH 2017 (\$ MILLIONS)</i>	97
OPPORTUNITIES IN THE VIRAL PANDEMIC INFECTIOUS DISEASE DIAGNOSIS AND TREATMENT MARKET	97
OPPORTUNITIES IN THE HIV/AIDS MARKET	97
Diagnostics	97
Pharmaceuticals	98
Immediate Term Priorities	99
Medium Term Priorities	99
OPPORTUNITIES IN THE HEPATITIS MARKET	100
Pharmaceutical Opportunities in the Hepatitis Market	100
CHAPTER 7 BACTERIAL PANDEMIC THREATS AND TREATMENTS	102
ANTIBACTERIAL RESISTANCE	102
THE MICROBIOLOGY OF BACTERIAL RESISTANCE	102
MECHANISMS OF RESISTANCE	103
METHODS OF RESISTANCE	103
Beta-Lactamase Production	103
Importing Resistance from Other Organisms	104
Alteration of Binding Sites to Circumvent Anti-Infective Effectiveness	105
Antibiotic Discharge	105
PRIMARY REASONS FOR ANTIBIOTIC RESISTANCE	105
BROAD-SPECTRUM PRESCRIPTIONS	105
PATIENT PRESSURE	106
SURVEILLANCE OF MICROBIAL RESISTANCE TO ANTIBIOTICS	106
RESISTANCE BY CLASS OF ANTIBIOTIC	106
<i>TABLE 53 ANTIBIOTIC RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED</i>	106
INCIDENCES OF ANTIBIOTIC RESISTANCE	107
ANTIBIOTIC RESISTANCE IN EUROPE	107
MRSA INFECTIONS IN MALAYSIA	107

TOPIC	PAGE NO.
ANTIBIOTIC RESISTANCE IN THE U.S.	107
VANCOMYCIN-RESISTANT ENTEROCOCCUS (VRE)	107
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)	108
CLOSTRIDIUM DIFFICILE (C. DIFFICILE)	108
TUBERCULOSIS (TB)	108
<i>TABLE 54 PROJECTED GLOBAL MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)</i>	108
EPIDEMIOLOGY OF TB	109
GEOGRAPHIC PREVALENCE	109
FINANCING CONTROL EFFORTS	110
DIAGNOSING TB	110
Smear Microscopy	110
Phage-based Diagnostics	110
Nucleic Acid Amplification Technologies (NAAT)	110
<i>TABLE 55 PROJECTED GLOBAL MARKET FOR TB DIAGNOSTIC TESTS, THROUGH 2017 (\$ MILLIONS)</i>	111
PHARMACEUTICAL TREATMENTS FOR TB	111
<i>TABLE 56 CURRENTLY AVAILABLE TREATMENTS FOR TB WITH BRAND NAME, GENERIC NAME AND MANUFACTURER, 2012</i>	111
MARKET FOR TB PHARMACEUTICAL TREATMENTS	112
<i>TABLE 57 PROJECTED GLOBAL MARKET FOR TB PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	112
REGIONAL ANALYSIS	112
<i>TABLE 58 PROJECTED GLOBAL MARKET FOR DIAGNOSTIC TB PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	113
<i>TABLE 59 PROJECTED GLOBAL MARKET FOR TB PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	113
AMERICAS	113
<i>TABLE 60 PROJECTED AMERICAS MARKET FOR TB DIAGNOSTIC PRODUCTS THROUGH 2017 (\$ MILLIONS)</i>	114
<i>TABLE 61 PROJECTED AMERICAS MARKET FOR TB PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	114
EMRA	114
<i>TABLE 62 PROJECTED EMRA MARKET FOR TB DIAGNOSTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	115
<i>TABLE 63 PROJECTED EMRA MARKET FOR TB PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	115
ASIA	115
<i>TABLE 64 PROJECTED ASIAN MARKET FOR TB DIAGNOSTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	116
<i>TABLE 65 PROJECTED ASIAN MARKET FOR TB PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	116
OPPORTUNITIES IN THE TUBERCULOSIS MARKET	116
PREVENTION	116
<i>TABLE 66 CURRENT TB VACCINES IN DEVELOPMENT</i>	117
DIAGNOSTICS	117
TREATMENT	117
<i>TABLE 67 PHARMACEUTICALS IN DEVELOPMENT FOR THE TREATMENT OF TB, 2012</i>	118

TOPIC	PAGE NO.
CHAPTER 8 PARASITIC PANDEMIC THREATS AND TREATMENTS	120
CLIMATE CHANGE AND VECTOR-BORNE DISEASES	120
MALARIA	120
<i>TABLE 68 ESTIMATED 2010 GLOBAL MALARIA CASES AND DEATHS, WITH RATE OF DECREASE OF MALARIA DEATHS BY REGION* SINCE 2000</i>	120
Cause of Malaria	121
<i>TABLE 69 PROJECTED GLOBAL MARKET FOR MALARIA PREVENTION, DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)</i>	121
Interventional Techniques to Minimize Exposure to Malarial Vectors	122
<i>TABLE 70 PROJECTED GLOBAL MARKET FOR INSECTICIDE-TREATED NETS, THROUGH 2017 (\$ MILLIONS)</i>	122
Diagnosis of Malaria	122
<i>TABLE 71 PROJECTED GLOBAL MARKET FOR MALARIAL DIAGNOSTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	123
Treatment of Malaria	123
<i>TABLE 72 PROJECTED GLOBAL MARKET FOR MALARIA DRUG TREATMENTS, THROUGH 2017 (\$ MILLIONS)</i>	123
Regional Analysis	123
<i>TABLE 73 PROJECTED GLOBAL MARKET FOR MALARIAL PANDEMIC PREVENTION, DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	124
The Americas	124
<i>TABLE 74 PROJECTED AMERICAS MARKET FOR MALARIA PREVENTATIVE, DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS THROUGH 2017 (\$ MILLIONS)</i>	124
<i>TABLE 75 MALARIAL PREVENTION PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	125
<i>TABLE 76 MALARIAL DIAGNOSTIC PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	125
<i>TABLE 77 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	126
EMRA	126
<i>TABLE 78 PROJECTED EMRA MARKET FOR MALARIAL PREVENTATIVE, DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS THROUGH 2017 (\$ MILLIONS)</i>	126
<i>TABLE 79 MALARIAL PREVENTATIVE PRODUCT MARKET IN THE EMRA BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	127
<i>TABLE 80 MALARIAL DIAGNOSTIC PRODUCT MARKET IN THE EMRA BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	127
<i>TABLE 81 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN THE EMRA BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	128
Asia	128
<i>TABLE 82 PROJECTED ASIA MARKET FOR MALARIA PREVENTATIVE, DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)</i>	128
<i>TABLE 83 MALARIAL PREVENTION PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	129
<i>TABLE 84 MALARIAL DIAGNOSTIC PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	129
<i>TABLE 85 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	130

TOPIC	PAGE NO.
OPPORTUNITIES IN THE MALARIAL DISEASE MARKET	130
Diagnostic Testing	130
Pharmaceutical Products	130
CHAPTER 9 REGULATIONS	132
CREATING DRUG TREATMENTS	132
<i>TABLE 86 PROCESS OF CREATING DRUG TREATMENTS IN THE U.S.</i>	132
REGIONAL REGULATIONS	133
THE AMERICAS	133
Canada	133
EMA	134
Diagnostic Products in EU	134
ASIA	134
Japan	134
Diagnostic Regulations	135
Pharmaceutical Regulations	135
China	135
India	135
CHAPTER 10 PHARMACEUTICAL TREATMENT PIPELINE	138
EMERGING TRENDS IN DIAGNOSTIC PRODUCTS	138
ANTIBIOTIC-RESISTANT INFECTIONS	138
EMERGING TRENDS IN PHARMACEUTICAL PRODUCTS	138
HIV/AIDS	138
Gilead Sciences	139
GlaxoSmithKline	139
HEPATITIS	139
Gilead Sciences	139
Janssen Pharmaceuticals/Tibotec Pharmaceuticals	140
Merck	140
Roche	140
Boehringer Ingelheim	140
Vertex Pharmaceuticals	141
INFLUENZA	141
VaxInnate	141
PHARMACEUTICAL TREATMENT PRODUCT PIPELINE	141
<i>TABLE 87 PANDEMIC DISEASE PHARMACEUTICAL PRODUCT PIPELINE, 2012</i>	141
CHAPTER 11 PATENT ANALYSIS	149
PHARMACEUTICAL PATENTS ISSUED BY COMPANY, APPROVAL DATE AND DISEASE	149
<i>TABLE 88 PANDEMIC PHARMACEUTICAL AND VACCINE PATENTS (FEBRUARY 2006-DECEMBER 2012)</i>	150
DIAGNOSTIC PATENTS ISSUED BY COMPANY, APPROVAL DATE AND DISEASE	154
<i>TABLE 89 PANDEMIC DIAGNOSTIC PATENTS (MARCH 2005 THROUGH DECEMBER 2012)</i>	154
PATENTS ISSUED BY COMPANY	155

TOPIC	PAGE NO.
<i>TABLE 90 PANDEMIC PHARMACEUTICAL AND VACCINE PRODUCT PATENTS (JANUARY 2005 THROUGH DECEMBER 2012)</i>	155
<i>TABLE 91 PANDEMIC DIAGNOSTIC PRODUCT PATENTS (JANUARY 2005 THROUGH DECEMBER 2012)</i>	156
PATENTS ISSUED BY COUNTRY	157
<i>TABLE 92 PANDEMIC PRODUCT DIAGNOSIS AND TREATMENT PATENTS, BY COUNTRY (JANUARY 2005 THROUGH DECEMBER 2012)</i>	157
PATENTS ISSUED, BY DISEASE	157
<i>TABLE 93 PATENTS ISSUED FOR DIAGNOSIS AND TREATMENT OF PANDEMIC DISEASES (MARCH 2005 THROUGH OCTOBER 2012)</i>	158
<i>FIGURE 9 DIAGNOSTIC AND PHARMACEUTICAL PATENTS ISSUED (BETWEEN MARCH 2005 AND DECEMBER 2012) (%)</i>	158
CHAPTER 12 COMPANY DIRECTORY	161
ABBOTT LABORATORIES	161
<i>TABLE 94 ABBOTT PHARMACEUTICAL PRODUCTS</i>	161
<i>TABLE 95 ABBOTT DIAGNOSTIC PRODUCTS</i>	161
ALERE	161
<i>TABLE 96 ALERE DIAGNOSTIC PRODUCTS</i>	162
ALFA SCIENTIFIC DESIGNS	162
<i>TABLE 97 ALFA SCIENTIFIC DESIGNS DIAGNOSTIC PRODUCTS</i>	163
ANADYS PHARMACEUTICALS (SEE ROCHE)	163
ATLAS LINK BIOTECH CO, LTD	163
<i>TABLE 98 ATLAS LINK BIOTECH DIAGNOSTIC PRODUCTS</i>	163
BAXTER HEALTHCARE	163
<i>TABLE 99 BAXTER PHARMACEUTICAL PRODUCTS</i>	164
BAYER AG	164
<i>TABLE 100 BAYER PHARMACEUTICAL PRODUCTS</i>	164
BIO-RAD LABORATORIES	164
<i>TABLE 101 BIO-RAD DIAGNOSTIC PRODUCTS</i>	165
BOEHRINGER INGELHEIM GMBH	165
<i>TABLE 102 BOEHRINGER INGELHEIM PHARMACEUTICAL PRODUCTS</i>	165
BRISTOL-MYERS SQUIBB COMPANY	166
<i>TABLE 103 BRISTOL-MYERS SQUIBB PHARMACEUTICAL PRODUCTS</i>	166
CREATIVE DIAGNOSTICS	166
<i>TABLE 104 CREATIVE DIAGNOSTICS DIAGNOSTIC PRODUCTS</i>	167
DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS, INC	167
<i>TABLE 105 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS DIAGNOSTIC PRODUCTS</i>	167
DIASORIN	168
<i>TABLE 106 DIAGNOSTIC PRODUCTS</i>	168
EMERGENT BIOSOLUTIONS	168
<i>TABLE 107 PHARMACEUTICAL PRODUCTS</i>	169
ENANTA PHARMACEUTICALS	169
ENZO BIOCHEM	169
<i>TABLE 108 ENZO BIOCHEM DIAGNOSTIC PRODUCTS</i>	169
FIRST DIAGNOSTIC LLC	170
<i>TABLE 109 DIAGNOSTIC PRODUCT</i>	170
GILEAD SCIENCES, INC.	170

TOPIC	PAGE NO.
<i>TABLE 110 GILEAD SCIENCES PHARMACEUTICAL PRODUCTS</i>	171
GLAXOSMITHKLINE	171
<i>TABLE 111 GSK PHARMACEUTICAL PRODUCTS</i>	171
HOME ACCESS HEALTH, INC	172
<i>TABLE 112 HOME ACCESS HEALTH DIAGNOSTIC PRODUCTS</i>	172
HUMAN GENOME SCIENCES (SEE GLAXOSMITHKLINE)	172
IDENIX PHARMACEUTICALS	172
IMMUNOSTICS	173
<i>TABLE 113 IMMUNOSTICS DIAGNOSTIC PRODUCTS</i>	173
IND DIAGNOSTIC, INC.	173
<i>TABLE 114 IND DIAGNOSTIC PRODUCTS</i>	173
INVERNESS MEDICAL INNOVATIONS (SEE ALERE)	174
JANSSEN THERAPEUTICS (FORMERLY TIBOTEC THERAPEUTICS)	174
<i>TABLE 115 JANSSEN THERAPEUTICS PHARMACEUTICAL PRODUCTS</i>	174
MERCK & COMPANY, INC.	174
<i>TABLE 116 MERCK PHARMACEUTICAL PRODUCTS</i>	175
NOVARTIS PHARMACEUTICAL CORPORATION	175
<i>TABLE 117 NOVARTIS DIAGNOSTIC PRODUCTS</i>	176
ORASURE TECHNOLOGIES, INC.	176
<i>TABLE 118 ORASURE DIAGNOSTIC PRODUCTS</i>	176
ORTHO CLINICAL DIAGNOSTICS	176
<i>TABLE 119 ORTHO DIAGNOSTIC PRODUCTS</i>	177
PFIZER, INC.	177
<i>TABLE 120 PFIZER PHARMACEUTICAL PRODUCTS</i>	177
PRINCETON BIOMEDITECH CORPORATION	178
<i>TABLE 121 PRINCETON BIOMEDITECH DIAGNOSTIC PRODUCTS</i>	178
PROTEIN SCIENCES CORPORATION	178
ROCHE LABORATORIES (HOFFMANN-LA ROCHE INC)	179
<i>TABLE 122 ROCHE PHARMACEUTICAL PRODUCTS</i>	179
RIB-X PHARMACEUTICALS	179
ROMARK LABORATORIES	180
SANOFI PASTEUR	180
<i>TABLE 123 SANOFI PASTEUR PHARMACEUTICAL PRODUCTS</i>	180
SCICLONE PHARMACEUTICALS	181
<i>TABLE 124 SCICLONE PHARMACEUTICALS PHARMACEUTICAL PRODUCTS</i>	181
SHANGHAI KEHUA BIO-ENGINEERING CO, LTD	181
<i>TABLE 125 SHANGHAI KEHUA BIO-ENGINEERING DIAGNOSTIC PRODUCTS</i>	181
STANDARD DIAGNOSTICS, INC	182
<i>TABLE 126 STANDARD DIAGNOSTICS DIAGNOSTIC PRODUCTS</i>	182
TRINITY BIOTECH PLC	183
<i>TABLE 127 TRINITY BIOTECH DIAGNOSTIC PRODUCTS</i>	183
VERTEX PHARMACEUTICALS	183
<i>TABLE 128 VERTEX PHARMACEUTICALS PHARMACEUTICAL PRODUCTS</i>	183
VIIV HEALTHCARE	184
<i>TABLE 129 VIIV HEALTHCARE PHARMACEUTICAL PRODUCTS</i>	184

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE PROJECTED MARKET FOR PANDEMIC INFECTIOUS DISEASE PRODUCTS, BY DISEASE TYPE, THROUGH 2017 (\$ MILLIONS)	7
TABLE 1 DISEASE-CAUSING BACTERIA, PARASITES, AND VIRUSES IDENTIFIED BETWEEN 1973 AND 2009	10
TABLE 2 HISTORY OF ANTIBIOTIC DISCOVERY AND APPROVAL, 1935-2003	13
TABLE 3 CDC'S SIX PHASES OF CLASSIFICATION OF VIRAL PANDEMICS	14
TABLE 4 MAJOR INFECTIOUS DISEASES WITH TYPE OF DISEASE, NUMBER OF CASES, AND POTENTIAL AS A PANDEMIC, 2011	15
TABLE 5 TECHNOLOGIES TO ADDRESS POTENTIAL PANDEMIC THREATS	17
TABLE 6 DISEASES THAT COULD BE OR HAVE BEEN WEAPONIZED	18
TABLE 7 SELECTED MERGERS AND ACQUISITIONS, 2008-2012 (\$ MILLIONS)	25
TABLE 8 MAJOR MANUFACTURERS OF VACCINES FOR CURRENT AND POTENTIAL PANDEMICS	28
TABLE 9 HEPATITIS B AND C DIAGNOSTIC PRODUCT MARKET BY TYPE OF TEST, 2011 (\$ MILLIONS/%)	33
TABLE 10 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND C, 2012	33
TABLE 11 HEPATITIS B AND C TREATMENT MANUFACTURER MARKET STANDING, BY REVENUE, 2011 (\$ MILLIONS)	36
TABLE 12 VACCINES AND MEDICATIONS FOR THE TREATMENT OF HEPATITIS, 2012	37
TABLE 13 HIV DIAGNOSTIC PRODUCT MARKET SHARE, 2011 (\$ MILLIONS/%)	38
TABLE 14 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HIV/AIDS, 2012	38
TABLE 15 HIV LIFE CYCLE	40
TABLE 16 FDA-APPROVED GENERIC DRUGS FOR TREATMENT OF HIV, 2004 TO 2012	41
TABLE 17 CURRENTLY APPROVED PHARMACEUTICAL PRODUCTS FOR TREATMENT OF HIV/AIDS, 2012	43
TABLE 18 HIV TREATMENT MARKET BY MANUFACTURER, 2011 (\$ MILLIONS)	44
TABLE 19 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF PANDEMIC INFLUENZA, 2012	46
TABLE 20 CURRENT PHARMACEUTICALS APPROPRIATE FOR TREATMENT OF PANDEMIC INFLUENZA	47
TABLE 21 WHO RECOMMENDED MOSQUITO NETTING, 2012	48
TABLE 22 AVAILABLE MALARIA DIAGNOSTIC METHODS	49
TABLE 23 CURRENT RAPID DIAGNOSTIC TESTS FOR DETECTION OF MALARIA	49
TABLE 24 PHARMACEUTICAL PRODUCTS USED TO TREAT MALARIA, 2012	51
TABLE 25 CURRENT DIAGNOSTIC TESTS FOR DETECTION OF TUBERCULOSIS, 2012	52
TABLE 26 DRUGS USED TO TREAT TB	52
TABLE 27 CAUSATIVE ORGANISMS FOR PANDEMIC DISEASES	55
TABLE 28 VACCINES AND MEDICATIONS FOR THE TREATMENT OF ANTHRAX, 2012	56
TABLE 29 CURRENT DIAGNOSTIC TESTS FOR CHOLERA	57
TABLE 30 CDC CLASSIFICATION OF HIV INFECTION	62
TABLE 31 PROJECTED NEED FOR API TO MEET CORE ARV PRODUCT REQUIREMENTS, 2011 AND 2015	69

TABLE HEADING	PAGE NO.
TABLE 32 PROJECTED GLOBAL MARKET FOR VIRAL HIV AND HEPATITIS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	80
TABLE 33 PROJECTED GLOBAL MARKET FOR DIAGNOSTIC PRODUCTS USED TO DETECT HIV AND HEPATITIS PANDEMIC DISEASES, THROUGH 2017 (\$ MILLIONS)	81
TABLE 34 PROJECTED GLOBAL MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	83
TABLE 35 HEPATITIS CHARACTERISTICS BY TYPE	84
TABLE 36 PROJECTED GLOBAL MARKET FOR HEPATITIS DIAGNOSTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)	85
TABLE 37 PROJECTED GLOBAL MARKET FOR HEPATITIS VACCINE AND PHARMACEUTICALS, THROUGH 2017 (\$ MILLIONS)	86
TABLE 38 PROJECTED REVENUE FROM HEPATITIS A TREATMENTS, THROUGH 2017 (\$ MILLIONS)	86
TABLE 39 PROJECTED GLOBAL REVENUE FROM HEPATITIS PHARMACEUTICALS AND VACCINATIONS, THROUGH 2017 (\$ MILLIONS)	87
TABLE 40 PROJECTED GLOBAL REVENUE FROM HEPATITIS C PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)	87
TABLE 41 PROJECTED GLOBAL MARKET FOR VIRAL PANDEMIC DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY REGION, THROUGH 2017 (\$ MILLIONS)	89
TABLE 42 PROJECTED GLOBAL MARKET FOR VIRAL PANDEMIC DIAGNOSTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)	89
TABLE 43 PROJECTED GLOBAL MARKET FOR PANDEMIC PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	91
TABLE 44 PROJECTED AMERICAS MARKET FOR VIRAL PANDEMIC DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	92
TABLE 45 PROJECTED MARKET FOR VIRAL PANDEMIC DIAGNOSTIC PRODUCTS IN THE AMERICAS, THROUGH 2017 (\$ MILLIONS)	93
TABLE 46 PROJECTED MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS IN THE AMERICAS, THROUGH 2017 (\$ MILLIONS)	93
TABLE 47 PROJECTED EMRA MARKET FOR VIRAL PANDEMIC DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	94
TABLE 48 PROJECTED EMRA MARKET FOR VIRAL PANDEMIC DIAGNOSTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)	94
TABLE 49 PROJECTED EMRA MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	95
TABLE 50 PROJECTED ASIAN MARKET FOR VIRAL PANDEMIC DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	95
TABLE 51 PROJECTED MARKET FOR VIRAL PANDEMIC DIAGNOSTIC PRODUCTS IN ASIA, THROUGH 2017 (\$ MILLIONS)	96
TABLE 52 PROJECTED MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS IN ASIA, THROUGH 2017 (\$ MILLIONS)	97
TABLE 53 ANTIBIOTIC RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED	106
TABLE 54 PROJECTED GLOBAL MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)	108
TABLE 55 PROJECTED GLOBAL MARKET FOR TB DIAGNOSTIC TESTS, THROUGH 2017 (\$ MILLIONS)	111
TABLE 56 CURRENTLY AVAILABLE TREATMENTS FOR TB WITH BRAND NAME, GENERIC NAME AND MANUFACTURER, 2012	111

TABLE HEADING	PAGE NO.
TABLE 57 PROJECTED GLOBAL MARKET FOR TB PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	112
TABLE 58 PROJECTED GLOBAL MARKET FOR DIAGNOSTIC TB PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)	113
TABLE 59 PROJECTED GLOBAL MARKET FOR TB PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)	113
TABLE 60 PROJECTED AMERICAS MARKET FOR TB DIAGNOSTIC PRODUCTS THROUGH 2017 (\$ MILLIONS)	114
TABLE 61 PROJECTED AMERICAS MARKET FOR TB PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	114
TABLE 62 PROJECTED EMRA MARKET FOR TB DIAGNOSTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)	115
TABLE 63 PROJECTED EMRA MARKET FOR TB PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	115
TABLE 64 PROJECTED ASIAN MARKET FOR TB DIAGNOSTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)	116
TABLE 65 PROJECTED ASIAN MARKET FOR TB PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	116
TABLE 66 CURRENT TB VACCINES IN DEVELOPMENT	117
TABLE 67 PHARMACEUTICALS IN DEVELOPMENT FOR THE TREATMENT OF TB, 2012	118
TABLE 68 ESTIMATED 2010 GLOBAL MALARIA CASES AND DEATHS, WITH RATE OF DECREASE OF MALARIA DEATHS BY REGION* SINCE 2000	120
TABLE 69 PROJECTED GLOBAL MARKET FOR MALARIA PREVENTION, DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)	121
TABLE 70 PROJECTED GLOBAL MARKET FOR INSECTICIDE-TREATED NETS, THROUGH 2017 (\$ MILLIONS)	122
TABLE 71 PROJECTED GLOBAL MARKET FOR MALARIAL DIAGNOSTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)	123
TABLE 72 PROJECTED GLOBAL MARKET FOR MALARIA DRUG TREATMENTS, THROUGH 2017 (\$ MILLIONS)	123
TABLE 73 PROJECTED GLOBAL MARKET FOR MALARIAL PANDEMIC PREVENTION, DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)	124
TABLE 74 PROJECTED AMERICAS MARKET FOR MALARIA PREVENTATIVE, DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS THROUGH 2017 (\$ MILLIONS)	124
TABLE 75 MALARIAL PREVENTION PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017 (\$ MILLIONS)	125
TABLE 76 MALARIAL DIAGNOSTIC PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017 (\$ MILLIONS)	125
TABLE 77 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017 (\$ MILLIONS)	126
TABLE 78 PROJECTED EMRA MARKET FOR MALARIAL PREVENTATIVE, DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS THROUGH 2017 (\$ MILLIONS)	126
TABLE 79 MALARIAL PREVENTATIVE PRODUCT MARKET IN THE EMRA BY REGION, THROUGH 2017 (\$ MILLIONS)	127
TABLE 80 MALARIAL DIAGNOSTIC PRODUCT MARKET IN THE EMRA BY REGION, THROUGH 2017 (\$ MILLIONS)	127
TABLE 81 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN THE EMRA BY REGION, THROUGH 2017 (\$ MILLIONS)	128

TABLE HEADING	PAGE NO.
TABLE 82 PROJECTED ASIA MARKET FOR MALARIA PREVENTATIVE, DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)	128
TABLE 83 MALARIAL PREVENTION PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017 (\$ MILLIONS)	129
TABLE 84 MALARIAL DIAGNOSTIC PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017 (\$ MILLIONS)	129
TABLE 85 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017 (\$ MILLIONS)	130
TABLE 86 PROCESS OF CREATING DRUG TREATMENTS IN THE U.S.	132
TABLE 87 PANDEMIC DISEASE PHARMACEUTICAL PRODUCT PIPELINE, 2012	141
TABLE 88 PANDEMIC PHARMACEUTICAL AND VACCINE PATENTS (FEBRUARY 2006-DECEMBER 2012)	150
TABLE 89 PANDEMIC DIAGNOSTIC PATENTS (MARCH 2005 THROUGH DECEMBER 2012)	154
TABLE 90 PANDEMIC PHARMACEUTICAL AND VACCINE PRODUCT PATENTS (JANUARY 2005 THROUGH DECEMBER 2012)	155
TABLE 91 PANDEMIC DIAGNOSTIC PRODUCT PATENTS (JANUARY 2005 THROUGH DECEMBER 2012)	156
TABLE 92 PANDEMIC PRODUCT DIAGNOSIS AND TREATMENT PATENTS, BY COUNTRY (JANUARY 2005 THROUGH DECEMBER 2012)	157
TABLE 93 PATENTS ISSUED FOR DIAGNOSIS AND TREATMENT OF PANDEMIC DISEASES (MARCH 2005 THROUGH OCTOBER 2012)	158
TABLE 94 ABBOTT PHARMACEUTICAL PRODUCTS	161
TABLE 95 ABBOTT DIAGNOSTIC PRODUCTS	161
TABLE 96 ALERE DIAGNOSTIC PRODUCTS	162
TABLE 97 ALFA SCIENTIFIC DESIGNS DIAGNOSTIC PRODUCTS	163
TABLE 98 ATLAS LINK BIOTECH DIAGNOSTIC PRODUCTS	163
TABLE 99 BAXTER PHARMACEUTICAL PRODUCTS	164
TABLE 100 BAYER PHARMACEUTICAL PRODUCTS	164
TABLE 101 BIO-RAD DIAGNOSTIC PRODUCTS	165
TABLE 102 BOEHRINGER INGELHEIM PHARMACEUTICAL PRODUCTS	165
TABLE 103 BRISTOL-MYERS SQUIBB PHARMACEUTICAL PRODUCTS	166
TABLE 104 CREATIVE DIAGNOSTICS DIAGNOSTIC PRODUCTS	167
TABLE 105 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS DIAGNOSTIC PRODUCTS	167
TABLE 106 DIAGNOSTIC PRODUCTS	168
TABLE 107 PHARMACEUTICAL PRODUCTS	169
TABLE 108 ENZO BIOCHEM DIAGNOSTIC PRODUCTS	169
TABLE 109 DIAGNOSTIC PRODUCT	170
TABLE 110 GILEAD SCIENCES PHARMACEUTICAL PRODUCTS	171
TABLE 111 GSK PHARMACEUTICAL PRODUCTS	171
TABLE 112 HOME ACCESS HEALTH DIAGNOSTIC PRODUCTS	172
TABLE 113 IMMUNOSTICS DIAGNOSTIC PRODUCTS	173
TABLE 114 IND DIAGNOSTIC PRODUCTS	173
TABLE 115 JANSSEN THERAPEUTICS PHARMACEUTICAL PRODUCTS	174
TABLE 116 MERCK PHARMACEUTICAL PRODUCTS	175
TABLE 117 NOVARTIS DIAGNOSTIC PRODUCTS	176
TABLE 118 ORASURE DIAGNOSTIC PRODUCTS	176
TABLE 119 ORTHO DIAGNOSTIC PRODUCTS	177

TABLE HEADING	PAGE NO.
TABLE 120 PFIZER PHARMACEUTICAL PRODUCTS	177
TABLE 121 PRINCETON BIOMEDITECH DIAGNOSTIC PRODUCTS	178
TABLE 122 ROCHE PHARMACEUTICAL PRODUCTS	179
TABLE 123 SANOFI PASTEUR PHARMACEUTICAL PRODUCTS	180
TABLE 124 SCICLONE PHARMACEUTICALS PHARMACEUTICAL PRODUCTS	181
TABLE 125 SHANGHAI KEHUA BIO-ENGINEERING DIAGNOSTIC PRODUCTS	181
TABLE 126 STANDARD DIAGNOSTICS DIAGNOSTIC PRODUCTS	182
TABLE 127 TRINITY BIOTECH DIAGNOSTIC PRODUCTS	183
TABLE 128 VERTEX PHARMACEUTICALS PHARMACEUTICAL PRODUCTS	183
TABLE 129 VIIV HEALTHCARE PHARMACEUTICAL PRODUCTS	184

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE PROJECTED MARKET FOR PANDEMIC INFECTIOUS DISEASE PRODUCTS, BY REGION, 2012 AND 2017 (%)	7
FIGURE 1 TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET AND THEIR MARKET SHARE, 2011 (%)	36
FIGURE 2 MARKET SHARE FOR BRANDED HIV DRUGS BY MANUFACTURER, 2011 (%)	44
FIGURE 3 PROJECTED GLOBAL MARKET FOR DIAGNOSTIC PRODUCTS USED TO DETECT HIV AND HEPATITIS PANDEMIC DISEASES, 2012 AND 2017 (%)	81
FIGURE 4 GLOBAL MARKET FOR VIRAL PANDEMIC PHARMACEUTICAL PRODUCTS, 2012 AND 2017 (%)	83
FIGURE 5 MARKET SHARES FOR HEPATITIS C TREATMENTS, 2010 (%)	88
FIGURE 6 GLOBAL PANDEMIC VIRAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, 2012 AND 2017 (%)	89
FIGURE 7 GLOBAL PANDEMIC PHARMACEUTICAL MARKET, 2012 AND 2017 (%)	91
FIGURE 8 MARKET FOR PANDEMIC DIAGNOSTIC PRODUCTS IN ASIA 2012 AND 2017 (%)	96
FIGURE 9 DIAGNOSTIC AND PHARMACEUTICAL PATENTS ISSUED (BETWEEN MARCH 2005 AND DECEMBER 2012) (%)	158